RESONATE-2 Trial Results Most Likely To Move Ibrutinib to Frontline in 2016

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the importance of the RESONATE-2 Trial Results Most Likely To Move Ibrutinib to Frontline in 2016